CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 120 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.78 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,778,383 | +775.8% | 454,620 | +543.2% | 0.05% | +642.9% |
| Q2 2023 | $773,967 | +1.4% | 70,682 | -41.9% | 0.01% | +16.7% |
| Q4 2022 | $762,952 | +1073.8% | 121,683 | +711.1% | 0.01% | +500.0% |
| Q2 2021 | $65,000 | -98.2% | 15,003 | -97.0% | 0.00% | -98.6% |
| Q3 2020 | $3,630,000 | +545.9% | 501,368 | +211.9% | 0.07% | +762.5% |
| Q2 2020 | $562,000 | +577.1% | 160,764 | +185.8% | 0.01% | +60.0% |
| Q1 2020 | $83,000 | -79.1% | 56,250 | -27.7% | 0.01% | -58.3% |
| Q3 2019 | $398,000 | -90.3% | 77,800 | -86.4% | 0.01% | -91.7% |
| Q2 2019 | $4,097,000 | +1.7% | 572,200 | +88.6% | 0.14% | +3.6% |
| Q1 2019 | $4,029,000 | +2202.3% | 303,400 | +1266.7% | 0.14% | +1900.0% |
| Q4 2018 | $175,000 | +12.2% | 22,200 | +58.6% | 0.01% | 0.0% |
| Q3 2018 | $156,000 | -55.3% | 14,000 | -46.2% | 0.01% | -63.2% |
| Q2 2018 | $349,000 | +25.5% | 26,000 | -24.4% | 0.02% | -24.0% |
| Q3 2017 | $278,000 | – | 34,410 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,023,369 | $27,154,000 | 9.26% |
| Omega Fund Management, LLC | 551,477 | $7,401,000 | 5.46% |
| Foresite Capital Management III, LLC | 1,562,040 | $20,963,000 | 4.51% |
| Versant Venture Management, LLC | 1,048,601 | $14,072,225,000 | 4.39% |
| Boxer Capital, LLC | 2,094,000 | $28,101,000 | 3.18% |
| Opaleye Management Inc. | 697,500 | $9,360,000 | 2.42% |
| Abingworth LLP | 273,417 | $3,667,000 | 2.10% |
| DAFNA Capital Management LLC | 294,511 | $3,952,000 | 1.85% |
| NEXTHERA CAPITAL LP | 828,655 | $11,121,000 | 1.72% |
| Vivo Capital, LLC | 906,000 | $12,158,000 | 1.57% |